21 May 2026 -  Vertex Pharmaceuticals today announced that Health Canada has accepted for review a new drug submission for suzetrigine for the treatment of moderate to severe acute pain in adults. 

Suzetrigine is a selective NaV1.8 pain signal inhibitor that represents a new class of oral pain medicine; it is not an opioid or a non-steroidal anti-inflammatory drug.

Read Vertex Pharmaceuticals press release